LB2503
/ Legend Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 21, 2025
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1